VIRGINIA BIOTECHNOLOGY RESEARCH PARTNERSHIP AUTHORITY

REPORT ON AUDIT FOR THE YEAR ENDED JUNE 30, 2021

Auditor of Public Accounts
Staci A. Henshaw, CPA
www.apa.virginia.gov
(804) 225-3350
AUDIT SUMMARY

We have audited the basic financial statements of the Virginia Biotechnology Research Partnership Authority (Authority) as of and for the year ended June 30, 2021, and issued our report thereon, dated December 1, 2021. We were not engaged to audit the financial statements of the Authority’s discretely presented component unit, Virginia Biotechnology Research Park Corporation (Corporation); therefore, we did not express an opinion over the discretely presented component unit. Our report, included in the Authority’s Annual Report, is available on the Auditor of Public Accounts’ website at www.apa.virginia.gov.

Our audit of the Authority for the year ended June 30, 2021, found:

- fair presentation of the financial statements, in all material respects, as it relates to the Authority;
- disclaimer of opinion on the financial statements as it relates to the Corporation;
- no internal control findings and recommendations requiring management’s attention; and
- no instances of noncompliance or other matters required to be reported under Government Auditing Standards.
- TABLE OF CONTENTS -

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUDIT SUMMARY</td>
<td></td>
</tr>
<tr>
<td>INDEPENDENT AUDITOR’S REPORT</td>
<td>1-2</td>
</tr>
<tr>
<td>AGENCY OFFICIALS</td>
<td>3-4</td>
</tr>
</tbody>
</table>
INDEPENDENT AUDITOR’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States, the financial statements of the Virginia Biotechnology Research Partnership Authority (Authority) as of and for the year ended June 30, 2021, and the related notes to the financial statements, which collectively comprise the Authority’s basic financial statements, and have issued our report thereon dated December 1, 2021. Our report disclaims an opinion on the Authority’s discretely presented component unit, Virginia Biotechnology Research Partnership Corporation (Corporation), because we were not engaged to audit the Corporation.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Authority’s internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Authority’s internal control. Accordingly, we do not express an opinion on the effectiveness of the Authority’s internal control.
A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity’s financial statements will not be prevented or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

**Compliance and Other Matters**

As part of obtaining reasonable assurance about whether the Authority’s financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit and, accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under Government Auditing Standards.

**Purpose of this Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity’s internal control or on compliance. This report is an integral part of an audit performed in accordance with Government Auditing Standards in considering the entity’s internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

We discussed this report with management at an exit conference held on December 2, 2021.

Staci A. Henshaw
AUDITOR OF PUBLIC ACCOUNTS

ZLB/vks
VIRGINIA BIOTECHNOLOGY RESEARCH PARTNERSHIP AUTHORITY

As of June 30, 2021

BOARD OF DIRECTORS

Michael Rao, Ex-Officio and Chair
Mary Doswell, Vice Chair
Gail Letts, Secretary
J. Robert Mooney, Interim Treasurer
   Ken Ampy
   Eric Edwards
   Vida Williams
   Brian Ball, Ex-Officio
   Levar Stoney, Ex-Officio

Executive Director
Chandra Briggman

Officers to the Board
Sara Maddox, Assistant Secretary to the Board
VIRGINIA BIOTECHNOLOGY RESEARCH PARK CORPORATION
As of June 30, 2021

BOARD OF DIRECTORS

Michael Rao, Ex-Officio and Chair
Jennifer Finn, Vice Chair
John A. Vithoulkas, Ex-Officio and Secretary
Paul Nolde, Interim Treasurer

Karen Booth Adams
Brian Anderson
Bryan Bostic
Elizabeth Creamer
George Karles
Erin Powell
Lisa Sims
Joseph Tannery
Garret Westlake

Ex-Officio
John Budesky
Brian Ball
Joseph Casey
P. Srirama Rao
Levar Stoney

President and CEO
Chandra Briggman

Officers to the Board
Sara Maddox, Assistant Secretary to the Board